The vaccine candidate is currently being evaluated in a phase III clinical trial in the U.K. NVX-CoV2373 is a recombinant spike protein vaccine adjuvanted with Novavax's proprietary Matrix-M to enhance immune response.

Under the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021. The company will work with Medsafe, New Zealand's regulatory agency to obtain the necessary product approvals. Additional financial terms of the agreement were not disclosed.

Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.

Endo to provide fill-finish services for Novavax COVID-19 vaccine
Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's...

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...

AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...

Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...